89Zr-DFO-REGN3504 (Regeneron Pharmaceuticals)

N/A

Report date: 2025/09/24 17:41:39

Base Information

Drug Name89Zr-DFO-REGN3504 (Regeneron Pharmaceuticals)

Drug Alias NameN/A

ClassificationDiagnostic agent (In vivo)Radiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Nuclides > Zirconium > 89Zr +[4]

Mechanisms of ActionAnti-Programmed death-ligand 1

TargetsProgrammed death-ligand 1

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesRegeneron Pharmaceuticals Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesRegeneron Pharmaceuticals Inc

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A